Defining evolutionary trajectories in myelodysplastic syndromes and integrating them into prognostic models to improve risk stratification: The progevo machine learning approach
Ivan Civettini(Vita-Salute San Raffaele University), Daniele Ramazzotti(Azienda Ospedaliera San Gerardo), Rami S. Komrokji(Moffitt Cancer Center), David A. Sallman(Moffitt Cancer Center), Andrea Aroldi(Azienda Ospedaliera San Gerardo), Carlo Gambacorti‐Passerini(Azienda Ospedaliera San Gerardo), Eric Padron(Moffitt Cancer Center), Torsten Haferlach(Martin Luther Christian University), Zhuoer Xie(Mayo Clinic), Rocco Piazza(Azienda Ospedaliera San Gerardo), Luca Mologni(Azienda Ospedaliera San Gerardo), Matteo Della Porta(University of Milan), Alex Graudenzi(University of Milano-Bicocca), Federica Malighetti(University of Milano-Bicocca), Beatrice Manghisi, Valentina Crippa(University of Milano-Bicocca), María Díez‐Campelo(Complejo Hospitalario de Salamanca), Amer M. Zeidan(Yale Cancer Center), Matteo Villa(University of Milano-Bicocca), Onyee Chan(Moffitt Cancer Center), Uwe Platzbecker(National Center for Tumor Diseases), Giulia Maggioni(Humanitas University), Luca Lanino(Humanitas University), Monica Fumagalli(Azienda Ospedaliera San Gerardo), Pierre Fenaux(Université Paris Cité), Lorenza Borin(Azienda Ospedaliera San Gerardo), Fabrizio Cavalca(Azienda Ospedaliera San Gerardo), Najla Al Ali(Moffitt Cancer Center), Arianna Zappaterra(Azienda Ospedaliera San Gerardo)
Cited by 0
Related Papers
Clinical and biological implications of driver mutations in myelodysplastic syndromes
|Blood|2013|1.8k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
|Nature Genetics|2020|739